Crucell N.V. Announces Completion Of Acquisition Of SBL Vaccin AB

November 27, 2006 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

LEIDEN, NETHERLANDS -- (MARKET WIRE) -- November 23, 2006 -- Dutch biotechnology company Crucell N.V. (Euronext: CRXL) (NASDAQ: CRXL) (Swiss Exchange: CRX) announced today that it has completed the acquisition of SBL Vaccin AB.

Twitter
LinkedIn
Facebook
Email
Print

Mergers & acquisitions Europe